Skip to main content
  • Clinical
      |Clinical
    • Acute Coronary Syndromes
    • Cardiac Surgery
    • Covid-19
    • Heart Failure
    • Heart Health
    • Heart Rhythm
    • Hypertension
    • Interventional Cardiology
    • Mitral Valve
    • Pharmaceutics
    • Structural Heart Disease
    • TAVR
    • Tricuspid Valve
    • Vascular & Endovascular
  • Management
      |Management
    • Chest Pain Guidelines
    • Compensation
    • Economics
    • Education & Training
    • Legal News
    • Patient Care
    • Policy & Regulations
    • Professional Associations
    • Quality
    • Revenue
    • Staffing
  • Technology
      |Technology
    • AI
    • Cardiac Imaging
    • Cath Lab
    • CT
    • CVIS
    • ECG
    • Echo
    • EP Lab
    • Informatics
    • MRI
    • Nuclear Cardiology
    • Remote Monitoring
  • Videos
  • Conferences
      |Conferences
    • ACC
    • AHA
    • ASE
    • ASNC
    • ESC
    • EuroPCR
    • HFSA
    • HRS
    • HRS
    • SCAI
    • SCCT
    • SIIM
    • SNMMI
    • STS
    • TCT
    • VIVA
  • Custom Content
      |Custom Content
    • Experience Stories
    • Webinars & Videos
  • Subscribe
  • Forty Under 40 Award
      |Forty Under 40 Award
    • Class of 2026
    • Class of 2025

Search form

Home

News You Need to Know Today
Left bundle branch block after TAVR | FDA approves tirzepatide, Eli Lilly’s new type 2 diabetes drug
Tuesday, May 24, 2022
Link to Twitter Link to Facebook Link to Linkedin Link to Vimeo

Today's News and Trends

Left bundle branch block after TAVR hurts outcomes, even when no permanent pacemaker is required

Researchers tracked data from more than 2,000 TAVR patients, focusing on cardiovascular mortality and hospitalizations for heart failure. 

READ MORE >
Share on Twitter Share on Facebook Share on Linkedin

Left bundle branch block after TAVR hurts outcomes, even when no permanent pacemaker is required

Share on Twitter Share on Facebook Share on Linkedin
Researchers tracked data from more than 2,000 TAVR patients, focusing on cardiovascular mortality and hospitalizations for heart failure. 
READ MORE >

FDA approves tirzepatide, Eli Lilly’s new type 2 diabetes drug, and the company shares an estimated price

The medication, sold under the name Mounjaro, will be available in six different doses and come in an auto-injector pen.

READ MORE >
The FDA has cleared tirzepatide (Mounjaro) from Eli Lilly, a once-weekly injectable dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide receptor agonist (GLP-1) for improving glycemic control among adults with type 2 diabetes.
Share on Twitter Share on Facebook Share on Linkedin

FDA approves tirzepatide, Eli Lilly’s new type 2 diabetes drug, and the company shares an estimated price

Share on Twitter Share on Facebook Share on Linkedin
The FDA has cleared tirzepatide (Mounjaro) from Eli Lilly, a once-weekly injectable dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide receptor agonist (GLP-1) for improving glycemic control among adults with type 2 diabetes.
The medication, sold under the name Mounjaro, will be available in six different doses and come in an auto-injector pen.
READ MORE >

Featured Articles

TPV valves, CTO PCI and more: SCAI 2022 updates for interventional cardiologists

The first two days of SCAI 2022 were jam-packed with innovative technologies and late-breaking research.

READ MORE >
SCAI 2022 interventional cardiology TAVR CTO PCI TPV cath labs
Share on Twitter Share on Facebook Share on Linkedin

TPV valves, CTO PCI and more: SCAI 2022 updates for interventional cardiologists

Share on Twitter Share on Facebook Share on Linkedin
SCAI 2022 interventional cardiology TAVR CTO PCI TPV cath labs
The first two days of SCAI 2022 were jam-packed with innovative technologies and late-breaking research.
READ MORE >

Cusp overlap technique, optimized treatment strategy tied to significant improvements for TAVR patients

The research, presented at EuroPCR 2022 in Paris, represented an updated look at the Optimize PRO study, an ongoing analysis of patients treated with Medtronic’s self-expanding Evolut Pro and Pro+ TAVR systems.

READ MORE >
Transcatheter aortic valve replacement (TAVR) patients continue to benefit from an optimized pre- and post-procedural treatment strategy that utilizes the cusp overlap technique and the Evolut Pro and Pro+ TAVR valves, according to new findings presented at EuroPCR 2022 in Paris.
Share on Twitter Share on Facebook Share on Linkedin

Cusp overlap technique, optimized treatment strategy tied to significant improvements for TAVR patients

Share on Twitter Share on Facebook Share on Linkedin
Transcatheter aortic valve replacement (TAVR) patients continue to benefit from an optimized pre- and post-procedural treatment strategy that utilizes the cusp overlap technique and the Evolut Pro and Pro+ TAVR valves, according to new findings presented at EuroPCR 2022 in Paris.
The research, presented at EuroPCR 2022 in Paris, represented an updated look at the Optimize PRO study, an ongoing analysis of patients treated with Medtronic’s self-expanding Evolut Pro and Pro+ TAVR systems.
READ MORE >

How cardiologists can make an impact in the face of anti-abortion laws

“For patients with cardiovascular disease, abortion access is a critical part of their comprehensive cardiovascular and reproductive care,” according to the three authors of a new commentary piece in JAMA Cardiology.

READ MORE >
Doctor patient
Share on Twitter Share on Facebook Share on Linkedin

How cardiologists can make an impact in the face of anti-abortion laws

Share on Twitter Share on Facebook Share on Linkedin
Doctor patient
“For patients with cardiovascular disease, abortion access is a critical part of their comprehensive cardiovascular and reproductive care,” according to the three authors of a new commentary piece in JAMA Cardiology.
READ MORE >

New guidelines detail PFO management, including when to consider closure

The new guidance document was designed to provide helpful information on a topic "surrounded by controversy." 

READ MORE >
heart.png
Share on Twitter Share on Facebook Share on Linkedin

New guidelines detail PFO management, including when to consider closure

Share on Twitter Share on Facebook Share on Linkedin
heart.png
The new guidance document was designed to provide helpful information on a topic "surrounded by controversy." 
READ MORE >

In Case You Missed It

State of the industry: 7 big takeaways from a new report on salaries and job satisfaction in cardiology

With physician burnout on the rise and a massive physician shortage on the way, it’s more important now than ever to keep a close eye on how the country’s cardiologists—and their colleagues—are being paid. 

READ MORE >
Salary Survey Photo #2 (1).png
Share on Twitter Share on Facebook Share on Linkedin

State of the industry: 7 big takeaways from a new report on salaries and job satisfaction in cardiology

Share on Twitter Share on Facebook Share on Linkedin
Salary Survey Photo #2 (1).png
With physician burnout on the rise and a massive physician shortage on the way, it’s more important now than ever to keep a close eye on how the country’s cardiologists—and their colleagues—are being paid. 
READ MORE >

VIDEO: Factors responsible for cardiologist burnout

American College of Cardiology President Edward T. A. Fry, MD, discusses cardiologist burnout and how the pandemic accelerated the issue.

READ MORE >
edward_fry_acc_president_video_interview_2022.jpg
Share on Twitter Share on Facebook Share on Linkedin

VIDEO: Factors responsible for cardiologist burnout

Share on Twitter Share on Facebook Share on Linkedin
edward_fry_acc_president_video_interview_2022.jpg
American College of Cardiology President Edward T. A. Fry, MD, discusses cardiologist burnout and how the pandemic accelerated the issue.
READ MORE >

In Other News

Gadolinium can be used as substitute for iodine contrast in some interventional imaging procedures

Gadolinium might be an alternative, stop-gap solution for interventional procedures during the current iodine contrast shortage.

READ MORE >
A comparison between a traditional iodine contrast angiogram (left), and a gadolinium contrast angiogram (right). MRI gadolinium contrast is starting to be used in some interventional radiology procedures and is being considered in interventional cardiology due to the iodine contrast shortage.
Share on Twitter Share on Facebook Share on Linkedin

Gadolinium can be used as substitute for iodine contrast in some interventional imaging procedures

Share on Twitter Share on Facebook Share on Linkedin
A comparison between a traditional iodine contrast angiogram (left), and a gadolinium contrast angiogram (right). MRI gadolinium contrast is starting to be used in some interventional radiology procedures and is being considered in interventional cardiology due to the iodine contrast shortage.
Gadolinium might be an alternative, stop-gap solution for interventional procedures during the current iodine contrast shortage.
READ MORE >

Innovate Healthcare thanks our partners for supporting our newsletters.
Sponsorship has no influence on editorial content.

Interested in reaching our audiences, contact our team

*|LIST:ADDRESSLINE|*

You received this email because you signed up for newsletters from Innovate Healthcare.
Change your preferences or unsubscribe here

Contact Us  |  Unsubscribe from all  |  Privacy Policy

© Innovate Healthcare, a TriMed Media brand
Innovate Healthcare

Recent Newsletters

Medtech giant makes big move | The world’s top hospitals for heart surgery | New CPT codes | PET vs. SPECT | TAVR tech recalled
AI is gaining ground, but clinicians run the show | Siemens Healthineers doubles down | Electrophysiologist compensation
News Alert: FDA shares warning about heart valve tech after patient death
Cardiologist pay & productivity are up | FDA clears PE thrombectomy devices | Cardiology tech in spotlight | Gore's new approval
Cardiology salaries on the rise | The climbing costs of care | M&A trends | Siemens Healthineers, J&J make big business moves
Major MRI trends | Blood thinner recalled | When to perform PCI before TAVR | How to build a CCTA program | Steroids & the heart
CMS boosts coverage for heart failure tech | FDA approves CardioMEMS updates | LVADs linked to strokes, other risks
Newsletter archive
  • Home
  • News
  • Article Archive
  • Custom Content
  • Webinars
  • Press Releases
  • Content Studio
  • Advertising
  • Submit Press Release
  • Contact Us
  • Terms of Use
  • Privacy Policy
  • Cardiovascular Business
  • HealthExec
  • Radiology Business
  • Press Releases
  • Submit Press Release
© 2026 Innovate Healthcare | All Rights Reserved. | Terms of Use | Privacy Policy
Design by Adaptive Theme